IL6 and systemic-onset juvenile idiopathic arthritis: Anakinra and canakinumab have revolutionized the outcomes of Still’s disease in children (soJIA), being currently recommended as first-line DMARD therapy (similarly to IL-6 blockade with tocilizumab) as early as possible after the diagnosis is made, even in CYP with risk factors for developing Still’s lung disease as per data currently available [17].